{"id":"NCT02783482","sponsor":"Green Cross Corporation","briefTitle":"Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency","officialTitle":"An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-10","primaryCompletion":"2019-07","completion":"2019-07","firstPosted":"2016-05-26","resultsPosted":"2022-10-28","lastUpdate":"2022-12-09"},"enrollment":49,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Immunologic Deficiency Syndromes"],"interventions":[{"type":"BIOLOGICAL","name":"GC5107","otherNames":["IGIV","Immune globulin intravenous (human) solution, 10% liquid"]}],"arms":[{"label":"GC5107","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety, efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in subjects with Primary Humoral Immunodeficiency (PHID).","primaryOutcome":{"measure":"The Incidence of Acute Serious Bacterial Infections (SBI)","timeFrame":"One year","effectByArm":[{"arm":"28-day Schedule","deltaMin":0.04,"sd":null},{"arm":"21-day Schedule","deltaMin":0,"sd":null},{"arm":"Total","deltaMin":0.02,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":20,"countries":["United States","Canada"]},"refs":{"pmids":["34305948"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":49},"commonTop":["Headache","Nausea","Cough","Fatigue","Pyrexia"]}}